Results 121 to 130 of about 401,712 (176)

Norethindrone acetate and estradiol-induced endometrial hyperplasia

Obstetrics & Gynecology, 2000
To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of endometrial hyperplasia associated with unopposed 17beta-estradiol (E2), 1 mg.In a double-masked, randomized, multicenter study, 1176 healthy postmenopausal women 45 years of age or older without evidence of endometrial ...
R J, Kurman, J C, Félix, D F, Archer, N, Nanavati, J, Arce, D L, Moyer   +5 more
openaire   +2 more sources

Norethindrone in Serum After use of an oral Contraceptive Containing Norethindrone Acetate

Acta Obstetricia et Gynecologica Scandinavica, 1983
Abstract. The availability of norethindrone (NET) in serum was studied in 8 women after daily administration of a combination oral contraceptive pill (MinovlarR) containing 1 mg norethindrone acetate (NETA) and 50 μg ethinyl estradiol (EE2) from day 5 to day 25 of the menstrual cycle. The pill was taken daily at 9.30 a.m.
N N, Sarkar, V, Laumas, N, Agarwal, V, Hingorani, K R, Laumas   +4 more
openaire   +2 more sources

Clinical evaluation of norethindrone acetate in fertility control

American Journal of Obstetrics and Gynecology, 1965
A clinical evaluation of 300 Mexican women accumulating 5902 treatment cycles representing 454 woman-years with 4 mg norethindrone acetate and .05 mg ethinyl estradiol (Anovlar) is presented. Each woman was instructed to take 1 tablet daily for 20 consecutive days beginning on Cycle Day 5. Anovlar was virtually 100% effective.
E, RICE WRAY, O, GONZALEZ, S, FERRER, A, ARANDA ROSELL, M, MAQUEO, H, MUNGUIA   +5 more
openaire   +2 more sources

Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate

Acta Endocrinologica, 1982
Abstract. The metabolic clearance rate (MCR) of norethindrone acetate1 (NETA) and norethindrone (NET) levels in plasma were studied after an iv injection of [3H]NETA in three women before and at 1 week, 1, 2 and 6 months following the insertion of a single silastic subdermal implant releasing microquantities of NETA. No significant change in the MCR of
H, Singh, J P, Uniyal, P, Jha, D, Takker, K, Murguesan, V, Hingorani, K R, Laumas   +6 more
openaire   +2 more sources

Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate.

Journal of Pediatric and Adolescent Gynecology, 2017
P. Brady, S. Missmer, M. Laufer
semanticscholar   +2 more sources

Bioavailability of norethindrone and menstrual pattern after insertion of norethindrone acetate implants in rhesus monkeys

Contraception, 1991
Subdermal silastic implants releasing norethindrone acetate were inserted in five rhesus monkeys for a period of seven months. The serum norethindrone (NET) levels were estimated from blood samples collected fortnightly. There was an initial high level of NET followed by fluctuating levels of NET in 4 out of five monkeys.
P, Jha, K, Murugesan, A, Farooq
openaire   +2 more sources

Effect of Norethindrone Acetate Upon Gonadotrophin-Induced Ovarian Function

The Journal of Clinical Endocrinology & Metabolism, 1965
Ovarian function was successfully induced in 2 successive cycles in 2 amenorrheic women using urinary gonadotrophins. When 5 mg of norethindrone acetate was administered along with the gonadotrophin ovarian function persisted. It was concluded that this is further evidence that this dosage of norethindrone acetate inhibits ovulation by suppression of ...
M L, TAYMOR, T, RIZKALLAH
openaire   +2 more sources

Hydrolysis of Norethindrone Acetate by Fetal and Placental Tissue

New England Journal of Medicine, 1963
IT has been demonstrated that certain progestational agents given during pregnancy may result in masculinization of the female fetus.1 , 2 The agent most frequently implicated was norethindrone (Norlutin). This drug has now been largely superseded in clinical use by its more potent ester, norethindrone acetate (Norlutate).
G, BETZ, J C, WARREN
openaire   +2 more sources

A Contraceptive Vaginal Ring Releasing Norethindrone Acetate and Ethinyl Estradiol

Obstetrical & Gynecological Survey, 1994
A core design contraceptive vaginal ring (CVR) releasing 650 mcg of norethindrone acetate (NA) and 10, 20, 30 or 65 mcg of ethinyl estradiol (EE) daily was developed and tested in 99 women. The CVR inhibited ovulation well with 30 or 65 mcg EE. Vaginal bleeding was better controlled than in 23 control women using NA/EE oral contraceptives. Side effects
S A, Ballagh, D R, Mishell, M, Lacarra, D, Shoupe, T M, Jackanicz, P, Eggena   +5 more
openaire   +2 more sources

Radioimmunoassay of norethindrone: Serum levels of norethindrone in lactating women after insertion of a single silastic implant releasing norethindrone acetate

Contraception, 1978
A specific radioimmunoassay was developed for the estimation of norethindrone levels in the serum of lactating women. A conjugate of norethindrone-3-BSA was synthesized and antiserum raised against it in rabbits. The antiserum showed high affinity (1.5 x 10(9)M/L) and titer and was specific. The sensitivity of the assay was 125 pg/ml serum.
V, Laumas, B K, Malik, K, Jamal, U, Seth, N, Agarwal, V, Hingorani, K R, Laumas   +6 more
openaire   +2 more sources